Tirzepatide in Obesity-Driven Endometrial Cancer
NCT07065552
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
LCCC2415 examines the antiproliferative effect of tirzepatide on the endometrium of endometrial cancer (EC). This is a pre-operative window clinical study. Endometrial biopsy samples from patients before tirzepatide treatment will be compared to their post-intervention hysterectomy specimens. If archival tissue is unavailable, a fresh biopsy will be taken before tirzepatide treatment. Post-intervention tissue will be collected from the hysterectomy specimen.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Endometrial Cancer
- Obesity
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 18 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Last updated on ClinicalTrials.gov
- October 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
North Carolina · 1
- Lineberger Comprehensive Cancer Center · Chapel Hill, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.